Brain Computer Interface (BCI) Enables Thought-Controlled Walking after Spinal Cord Injury
24 Mayo 2023 - 10:30AM
ONWARD Medical N.V. (Euronext: ONWD), the medical technology
company creating innovative spinal cord stimulation therapies to
restore movement, function, and independence in people with spinal
cord injury (SCI), today announces a publication in Nature
showing that a wireless brain-computer interface (BCI) can use
thought to modulate ARC Therapy. Researchers reported that when
paired with ARC Therapy, an implanted BCI allowed an individual to
gain augmented control over when and how he moved his paralyzed
legs.
“This publication shows the remarkable potential
of ARC Therapy to be enhanced with the introduction of a BCI,
facilitating more natural movement based on the thoughts of a
person living with paralysis,” said Dave Marver, CEO of ONWARD. “We
have positioned ONWARD as a leader in the BCI field with our unique
understanding of spinal cord stimulation for people with SCI.”
“The BCI establishes a continuous link between
movement intentions and spinal cord stimulation, allowing for more
natural restoration of mobility,” said neuroscientist Grégoire
Courtine, professor at EPFL, and co-author of the Nature paper. “I
look forward to working with the ONWARD team to advance this
important new technology.”
The data published today are part of an ongoing
clinical feasibility study investigating the safety and preliminary
effectiveness of brain-controlled spinal cord stimulation after
SCI. The study is being coordinated by .NeuroRestore co-Directors –
Grégoire Courtine and Jocelyne Bloch, a neurosurgeon at Lausanne
University Hospital (CHUV) – as well as Guillaume Charvet, Head of
the Medical Device Development Lab at CEA-Leti / Clinatec.
All ONWARD devices and therapies, including but
not limited to ARC-IM, ARC-EX, and ARC Therapy, are investigational
and not available for commercial use.
About ONWARD Medical
ONWARD is a medical technology company creating
therapies to restore movement, function, and independence in people
with spinal cord injury (SCI) and movement disabilities. Building
on more than a decade of science and preclinical research conducted
at leading neuroscience laboratories, the Company has received nine
Breakthrough Device Designations from the U.S. Food and Drug
Administration for its ARC Therapy™ platform.
ONWARD® ARC Therapy, which can be delivered by
external ARC-EX™ or implantable ARC-IM™ systems, is designed to
deliver targeted, programmed spinal cord stimulation. Positive
results were presented in 2023 from the Company’s pivotal study,
called Up-LIFT, evaluating the ability for transcutaneous ARC
Therapy to improve upper extremity strength and function. The
Company is now preparing regulatory approval submissions for ARC-EX
for the US and Europe. In parallel, the Company is conducting
studies with its implantable ARC-IM platform, which demonstrated
positive interim clinical outcomes for improved blood pressure
regulation following SCI in 2022. These studies include combination
use of ARC-IM with a brain-computer interface (BCI).
Headquartered in Eindhoven, the Netherlands,
ONWARD has a Science and Engineering Center in Lausanne,
Switzerland and a U.S. office in Boston, Massachusetts. The Company
also has an academic partnership with .NeuroRestore, a
collaboration between EPFL, the Swiss Federal Institute of
Technology in Lausanne, and Lausanne University Hospital
(CHUV).
For more information, visit ONWD.com, and
connect with us on LinkedIn and YouTube.
For Media Enquiries:Aditi Roy,
VP Communicationsmedia@onwd.com
For Investor Enquiries:Lara
Smith Weber, CFOinvestors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in
this press release are forward-looking, which reflect the Company’s
or, as appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve several risks, uncertainties, and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties, and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition, and technology, can cause actual
events, performance, or results to differ significantly from any
anticipated development. Forward-looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions, or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release. All ONWARD devices and therapies referenced here,
including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are
investigational and not available for commercial use.
Onward Medical NV (EU:ONWD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Onward Medical NV (EU:ONWD)
Gráfica de Acción Histórica
De May 2023 a May 2024